Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators.

PURPOSE We studied oncologists' attitudes and behavior with regard to their participation in randomized clinical trials. METHODS We surveyed the 1,737 physician members of the Eastern Cooperative Oncology Group (ECOG) using the Physician Orientation Profile (POP), a self-administered mailed questionnaire. A response rate of 86% was achieved (1,485 of 1,737); each physician's actual patient accrual was recorded. RESULTS All respondents indicated that they had a systematic pattern of patient preselection for entry onto trials beyond the formal inclusion/exclusion trial criteria. Eighty-nine percent stated that improving patient quality of life rather than prolonging survival was more personally satisfying. Sixty-two percent did not enter a single patient during the 12-month period following the survey, while 10% entered 80% of all patients during that time. Physicians overestimated their accrual rate by a factor of 6. Eighty-three percent defined randomization and adherence to trial protocol as a serious challenge to their ability to make individualized treatment decisions. CONCLUSION This study raises questions regarding the following: (1) the perceived generalizability of trial findings, (2) the role of end points other than survival for clinical trials, (3) the consequences of physician overestimation of patient accrual, and (4) the impact of randomized trials on the behavior of clinicians. Further investigation into these critical issues will provide meaningful recommendations to enhance the future design, implementation, and conduct of randomized clinical trials in cancer.

[1]  T. Louis,et al.  Critical issues in the conduct and interpretation of clinical trials. , 1983, Annual review of public health.

[2]  R. Gelber,et al.  A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Weiss,et al.  Planning patient recruitment: fantasy and reality. , 1984, Statistics in medicine.

[4]  I. Tannock,et al.  When is a cancer treatment worthwhile? , 1990, The New England journal of medicine.

[5]  A. Rademaker,et al.  Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  F. Gifford The conflict between randomized clinical trials and the therapeutic obligation. , 1986, The Journal of medicine and philosophy.

[7]  C. Moinpour,et al.  Quality of life end points in cancer clinical trials: review and recommendations. , 1989, Journal of the National Cancer Institute.

[8]  C. Begg,et al.  Cooperative groups and community hospitals. Measurement of impact in the community hospitals , 1983, Cancer.

[9]  C. Begg,et al.  Eligibility and extrapolation in cancer clinical trials. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Taylor Km Physician participation in a randomized clinical trial for ocular melanoma. , 1992 .

[11]  Lacher Mj Patients and physicians as obstacles to a randomized trial. , 1981 .

[12]  S. Pocock,et al.  Estimation issues in clinical trials and overviews. , 1990, Statistics in medicine.

[13]  S. Pocock,et al.  Clinical Trials: A Practical Approach , 1984 .

[14]  C L Soskolne,et al.  Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. , 1984, The New England journal of medicine.

[15]  K. Taylor,et al.  Integrating conflicting professional roles: physician participation in randomized clinical trials. , 1992, Social science & medicine.

[16]  N K Aaronson,et al.  Quality of life assessment in clinical trials: methodologic issues. , 1989, Controlled clinical trials.

[17]  C. Begg Selection of patients for clinical trials. , 1988, Seminars in oncology.

[18]  R. Simon Patient heterogeneity in clinical trials. , 1980, Cancer treatment reports.

[19]  A. Strauss,et al.  Basics of qualitative research: Grounded theory procedures and techniques. , 1992 .

[20]  C. Soskolne,et al.  Physician response to informed consent regulations for randomized clinical trials , 1987, Cancer.

[21]  D. Sackett,et al.  Are the results of the extracranial-intracranial bypass trial generalizable? , 1987, The New England journal of medicine.

[22]  D. Cain,et al.  National cancer institute sponsored cooperative clinical trials , 1990, Cancer.

[23]  T. Morgan Planning the duration of accrual and follow-up for clinical trials. , 1985, Journal of chronic diseases.

[24]  R. H. Waterman,et al.  In search of excellence : lessons from America's best-run companies , 1983 .

[25]  B. Freedman Equipoise and the ethics of clinical research. , 1987, The New England journal of medicine.

[26]  B. Fisher On clinical trial participation. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M S Kramer,et al.  Scientific challenges in the application of randomized trials. , 1984, JAMA.

[28]  M. Bracken,et al.  Clinical trials and the acceptance of uncertainty. , 1987, British medical journal.

[29]  K. Taylor,et al.  Some thoughts on the future of clinical trials groups in cancer. , 1987, Cancer treatment reports.

[30]  R. Yancik,et al.  Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician's Patient Log. , 1987, Cancer treatment reports.

[31]  M. Kelner,et al.  Interpreting physician participation in randomized clinical trials: the Physician Orientation Profile. , 1987, Journal of health and social behavior.

[32]  G. Guyatt,et al.  Measuring quality of life in clinical trials: a taxonomy and review. , 1989, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[33]  Gail Mh Eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in cancer clinical trials. , 1985 .